New drug combo shows promise for Hard-to-Treat bone marrow disease

NCT ID NCT03359460

Completed Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a combination of two drugs, ibrutinib and lenalidomide, in 4 patients with myelodysplastic syndrome (MDS) who had not responded to or could not tolerate standard treatments. The main goal was to find the safest dose and identify side effects. While the approach aims to control the disease, the study is too small to draw broad conclusions about effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ibrutinib and lenalidomide
What this could lead to: If it works, this could point toward a new treatment option for people with myelodysplastic syndrome who have not responded to standard therapies.
What could go wrong: This is a very early, small phase 1 trial with only 4 participants, so results may not apply broadly. The combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes therapy related acute myeloid leukemia and myelodysplastic syndrome therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROME PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME SECONDARY MYELODYSPLASTIC SYNDROME THERAPY-RELATED MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.